BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

...Xetra:BAYN) for $240 million up front. In 2018, Versant’s Inception 4 start-up was acquired by Ophthotech...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...and technical operations from SVP of R&D and head of Israeli operations. Retinal disease company Iveric bio Inc....
...Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic...
BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

...biopharmas have announced snags to their trial plans. More are sure to follow. On Wednesday, Iveric bio Inc....
BioCentury | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

...counsel, effective Dec. 2. He was a member of law firm Dykema. Retinal disease company Iveric bio Inc....
...was chief development officer of Notable Labs Inc. Elizabeth S. Eaton, Staff Writer Ultragenyx Pharmaceutical Inc. MiMedx Group Inc. Iveric bio Inc. Agios...
BioCentury | Sep 17, 2019
Company News

Penn emerges from Novartis alliance a prolific source of cell, gene therapies

...six focused on gene therapy in 2018 alone, including deals with Johnson & Johnson (NYSE:JNJ), Iveric bio Inc....
BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

...not disclosed. Iveric gets rights to AAV gene therapies for LCA10 Ocular gene therapy company Iveric bio Inc....
...to treat Leber congenital amaurosis type 10 (LCA10) due to mutations in CEP290. Iveric (formerly Ophthotech...
...2A BioCentury Staff Cimzia, certolizumab pegol (CDP 870) lumateperone (ITI-007) Tamiflu, oseltamivir (GS 4104, Ro 64-0796) Exscientia Ltd. Genentech Inc. Intra-Cellular Therapies Inc. Iveric bio Inc. Pfizer...
BioCentury | Apr 19, 2019
Company News

Ophthotech rebrands as Iveric as focus turns to retinal gene therapies

...Ophthotech Corp. (NASDAQ:OPHT) changed its name and ticker to Iveric bio Inc. (NASDAQ:ISEE) as part of its shift...
...treat rhodopsin-mediated autosomal dominant retinitis pigmentosa (see "Gene Therapy Rising" ). Elizabeth S. Eaton, Staff Writer Ophthotech Corp. Iveric bio Inc....
BioCentury | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

...HtrA serine peptidase 1 (HTRA1) Preclinical studies suggest HTRA1 inhibitors could help treat dry AMD Ophthotech...
BioCentury | Nov 14, 2018
Translation in Brief

Gene therapy rising

...from animal proof-of-concept to IND-enabling studies. By licensing gene therapy programs at the preclinical stage, Ophthotech...
...others could help overcome the manufacturing bottleneck (see “Academia’s Manufacturing Problem” ). Through its partnerships, Ophthotech...
...apparent that gene therapy was going to play a major role in ophthalmology.” Glenn Sblendorio, Ophthotech...
BioCentury | Nov 2, 2018
Finance

Bye-bye, build-to-buy

...to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech...
...serine peptidase 1 (HTRA1) to treat age-related retinal diseases, including dry age-related macular degeneration (AMD). Ophthotech...
...IND for its lead HTRA1 inhibitor in late 2020. Versant gained a 12.5% stake in Ophthotech...
Items per page:
1 - 10 of 125
BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

...Xetra:BAYN) for $240 million up front. In 2018, Versant’s Inception 4 start-up was acquired by Ophthotech...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...and technical operations from SVP of R&D and head of Israeli operations. Retinal disease company Iveric bio Inc....
...Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic...
BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

...biopharmas have announced snags to their trial plans. More are sure to follow. On Wednesday, Iveric bio Inc....
BioCentury | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

...counsel, effective Dec. 2. He was a member of law firm Dykema. Retinal disease company Iveric bio Inc....
...was chief development officer of Notable Labs Inc. Elizabeth S. Eaton, Staff Writer Ultragenyx Pharmaceutical Inc. MiMedx Group Inc. Iveric bio Inc. Agios...
BioCentury | Sep 17, 2019
Company News

Penn emerges from Novartis alliance a prolific source of cell, gene therapies

...six focused on gene therapy in 2018 alone, including deals with Johnson & Johnson (NYSE:JNJ), Iveric bio Inc....
BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

...not disclosed. Iveric gets rights to AAV gene therapies for LCA10 Ocular gene therapy company Iveric bio Inc....
...to treat Leber congenital amaurosis type 10 (LCA10) due to mutations in CEP290. Iveric (formerly Ophthotech...
...2A BioCentury Staff Cimzia, certolizumab pegol (CDP 870) lumateperone (ITI-007) Tamiflu, oseltamivir (GS 4104, Ro 64-0796) Exscientia Ltd. Genentech Inc. Intra-Cellular Therapies Inc. Iveric bio Inc. Pfizer...
BioCentury | Apr 19, 2019
Company News

Ophthotech rebrands as Iveric as focus turns to retinal gene therapies

...Ophthotech Corp. (NASDAQ:OPHT) changed its name and ticker to Iveric bio Inc. (NASDAQ:ISEE) as part of its shift...
...treat rhodopsin-mediated autosomal dominant retinitis pigmentosa (see "Gene Therapy Rising" ). Elizabeth S. Eaton, Staff Writer Ophthotech Corp. Iveric bio Inc....
BioCentury | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

...HtrA serine peptidase 1 (HTRA1) Preclinical studies suggest HTRA1 inhibitors could help treat dry AMD Ophthotech...
BioCentury | Nov 14, 2018
Translation in Brief

Gene therapy rising

...from animal proof-of-concept to IND-enabling studies. By licensing gene therapy programs at the preclinical stage, Ophthotech...
...others could help overcome the manufacturing bottleneck (see “Academia’s Manufacturing Problem” ). Through its partnerships, Ophthotech...
...apparent that gene therapy was going to play a major role in ophthalmology.” Glenn Sblendorio, Ophthotech...
BioCentury | Nov 2, 2018
Finance

Bye-bye, build-to-buy

...to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech...
...serine peptidase 1 (HTRA1) to treat age-related retinal diseases, including dry age-related macular degeneration (AMD). Ophthotech...
...IND for its lead HTRA1 inhibitor in late 2020. Versant gained a 12.5% stake in Ophthotech...
Items per page:
1 - 10 of 125